Related Experiment Video
Updated: Feb 18, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Mcl-1 stabilization confers resistance to taxol in human gastric cancer
Abstract:
Taxol has been extensively used as an antineoplastic drug to treat human gastric cancer. However, the acquired drug resistance invariably develops and greatly limits the therapeutic efficacy of Taxol. Identification of the underlying resistance mechanisms may inform the development of new therapies of gastric cancers to Taxol treatment. Here we report that upregulation of Mcl-1 (Myeloid cell leukemia-1) confers acquired resistance to Taxol in human gastric cancer. Mcl-1 is shown to be stabilized in Taxol -resistant gastric cancer cells because of the hyper-activation of the PI3K/Akt signaling pathway. The increased Mcl-1 prevents of the permeabilization of the outer mitochondrial membrane, thereby blocking the Taxol-induced apoptosis. Furthermore, inhibition of Mcl-1 or PI3K/Akt pathway significantly reversed the resistant phenotype of Taxol-resistant human gastric cancer cells. Taken together, our findings broaden the view of PI3K/Akt pathway as an important regulator in Taxol acquired resistance, and implicate Mcl-1 as a specific therapeutic target for the treatment of Taxol-resistant human gastric cancer.
Insights
Upregulation of Myeloid cell leukemia-1 (Mcl-1) causes acquired Taxol resistance in gastric cancer by stabilizing Mcl-1 via the PI3K/Akt pathway. Inhibiting Mcl-1 or PI3K/Akt reverses this resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Taxol is a key antineoplastic drug for gastric cancer.
- Acquired Taxol resistance limits its therapeutic effectiveness.
- Understanding resistance mechanisms is crucial for developing new treatments.
Purpose of the Study:
- To identify mechanisms of acquired Taxol resistance in human gastric cancer.
- To investigate the role of Myeloid cell leukemia-1 (Mcl-1) in Taxol resistance.
- To explore the involvement of the PI3K/Akt signaling pathway.
Main Methods:
- Investigated Mcl-1 expression and stability in Taxol-resistant gastric cancer cells.
- Analyzed the activation status of the PI3K/Akt signaling pathway.
- Assessed the effects of Mcl-1 and PI3K/Akt inhibition on Taxol resistance.
Main Results:
- Upregulation and stabilization of Mcl-1 were observed in Taxol-resistant cells.
- Hyper-activation of the PI3K/Akt pathway was linked to Mcl-1 stabilization.
- Increased Mcl-1 inhibited Taxol-induced apoptosis by preventing mitochondrial outer membrane permeabilization.
- Inhibition of Mcl-1 or PI3K/Akt reversed the Taxol-resistant phenotype.
Conclusions:
- Mcl-1 upregulation, driven by PI3K/Akt hyper-activation, confers acquired Taxol resistance in gastric cancer.
- Mcl-1 acts by blocking Taxol-induced apoptosis.
- The PI3K/Akt pathway is a critical regulator of Taxol acquired resistance.
- Mcl-1 represents a potential therapeutic target for overcoming Taxol resistance in gastric cancer.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Abnormal Proliferation
Treatment Resistant Cancers